SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-039595
Filing Date
2021-07-30
Accepted
2021-07-30 17:01:06
Documents
46
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0621_actiniumpharma.htm   iXBRL 10-Q 903977
2 CERTIFICATION f10q0621ex31-1_actinium.htm EX-31.1 12417
3 CERTIFICATION f10q0621ex31-2_actinium.htm EX-31.2 13885
4 CERTIFICATION f10q0621ex32-1_actinium.htm EX-32.1 7219
5 CERTIFICATION f10q0621ex32-2_actinium.htm EX-32.2 6616
  Complete submission text file 0001213900-21-039595.txt   3417068

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE atnm-20210630.xsd EX-101.SCH 34535
7 XBRL CALCULATION FILE atnm-20210630_cal.xml EX-101.CAL 24973
8 XBRL DEFINITION FILE atnm-20210630_def.xml EX-101.DEF 147982
9 XBRL LABEL FILE atnm-20210630_lab.xml EX-101.LAB 309556
10 XBRL PRESENTATION FILE atnm-20210630_pre.xml EX-101.PRE 161627
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0621_actiniumpharma_htm.xml XML 292566
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36374 | Film No.: 211133348
SIC: 2834 Pharmaceutical Preparations